Related Experiment Video
Updated: Mar 28, 2026
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
4.8K
The potential of liquid biopsies.
Anna Buder1, Christian Tomuta, Martin Filipits
1Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Current Opinion in Oncology
|January 6, 2016
Summary
Liquid biopsy offers a non-invasive method for analyzing genetic alterations in nonsmall cell lung cancer (NSCLC). This approach aids in monitoring tumor burden and treatment response, though further research is needed for routine clinical use.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Nonsmall cell lung cancer (NSCLC) progression is linked to specific genetic alterations.
- Obtaining sufficient tumor tissue for genetic analysis in NSCLC can be challenging clinically.
- Liquid biopsy, analyzing blood for tumor-derived genetic material, presents a valuable alternative.
Purpose of the Study:
- To review the current status of liquid biopsy in NSCLC.
- To explore the clinical and research applications of liquid biopsy in NSCLC patients.
Main Methods:
- Review of existing literature on liquid biopsy in NSCLC.
- Analysis of tumor-specific genetic alterations in patient serum or plasma.
- Assessment of liquid biopsy for monitoring tumor burden and molecular changes during therapy.
Main Results:
- Liquid biopsy allows for temporal measurements of tumor burden and identification of emergent mutations during therapy.
- It is particularly useful for assessing response in EGFR-mutated NSCLC patients undergoing targeted therapy.
- Liquid biopsy provides a rapid and accessible method for evaluating tumor characteristics.
Conclusions:
- Liquid biopsy presents significant opportunities for NSCLC management and research.
- Further research is required to overcome limitations, such as the small amount of tumor material in blood and incomplete biomarker knowledge, for its integration into routine clinical practice.
